Mergers and Acquisitions in the IVD Market

Mergers and Acquisitions in the IVD Market

In vitro diagnostic (IVD) products continue to see positive sales growth in many categories. New products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture. In this environment, companies are making strategic acquisitions that simultaneously add a revenue stream and product innovation. Kalorama Information looks at these market transactions in Mergers and Acquisitions in the IVD Market, recording more than 220 acquisitions in the diagnostics industry from 2016 to June 2019.

Though some segments of the overall IVD market are still relatively small, they represent the biggest growth areas in the market. The report focuses on acquisitions in these growing segments of great market interest, anticipated to be a big part of the future of IVD, including the following:

• Next-Generation Sequencing (NGS)
• Cancer Testing (Liquid Biopsy)
• Companion Diagnostics

The merger and acquisition activities of major players in the market are of course of interest as well, therefore the report provides detailed discussion of activities of leading companies, including:

• Roche
• Abbott
• Danaher

Detailed listings of company buys are featured in the report:

• Selected Acquisitions of Diagnostic Companies, from 2018 to end June 2019
• Selected Acquisitions of Diagnostic Companies, 2016-2017

From 2018 to 2019, the report provides summaries of the market impact of numerous transactions, including:

• Danaher / Beckman Coulter Acquisitions in 2018 / 2019
• QIAGEN M&A Activity
• bioMérieux Activity in M&A
• Illumina Acquisitions of PacBio, Edico Genome

From 2016 to 2017, the report provides summaries of the market impact of numerous transactions, including:

• Abbott’s Acquisitions, Divestures and the Alere Deal
• Siemens’ M&A Activity in Recent Years
• Konica Minolta’s Acquisitions of Ambry Genetics and Invicro, Building a Presence in Precision Medicine
• Thermo’s Completion of the Patheon Acquisition
• Danaher’s Acquisition of Molecular Diagnostics Leader Cepheid for Nearly $4 Billion

The information presented in this report is the result of data gathered from government reports, company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press.